

## **INVO Bioscience to Report First Quarter 2022 Financial Results on Monday, May 16, 2022**

*Financial results to be released after market close;  
Conference call to be conducted at 4:30 pm ET*

SARASOTA, Fla., May 9, 2022 /PRNewswire/ — **INVO Bioscience, Inc. (NASDAQ: INVO)**, a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its first quarter 2022, ended March 31, 2022, after the market close on Monday, May 16, 2022. The Company has scheduled a conference call that same day, Monday, May 16, 2022, at 4:30 pm ET, to review the results.



### **First Quarter 2022 Conference Call Details**

**Date and Time:** Monday, May 16, 2022 at 4:30 pm ET

**Call-in Information:** Interested parties can access the conference call by dialing 833-756-0861 or 412-317-5751.

**Live Webcast Information:** Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at <https://www.invobioscience.com/investors/> or <https://app.webinar.net/6XQVP1XJjRA>.

**Replay:** A teleconference replay of the call will be available through May 23, 2022, at 877-344-7529 or 412-317-0088, replay access code # 4725753. A webcast replay will be available in the Investor Relations section of the Company's website at <https://www.invobioscience.com/investors/> for 90 days.

### **About INVO Bioscience**

We are a commercial-stage fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace by making fertility care accessible and inclusive to people around the world. Our flagship product is INVOcell®, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care.

This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as "IVC", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. The IVC procedure can deliver comparable results at a fraction of the cost of traditional in vitro fertilization ("IVF") and is a significantly more effective treatment than intrauterine insemination ("IUI"). Our commercialization strategy is focused on the opening of dedicated "INVO Centers" offering the INVOcell® and IVC procedure (with three centers in North America now operational), in addition to continuing to sell our technology solution into existing fertility clinics. For more information, please visit [www.invobio.com](http://www.invobio.com).

### **Safe Harbor Statement**

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at [www.sec.gov](http://www.sec.gov). We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

### **For more information, please contact:**

#### **INVO Bioscience**

##### **Steve Shum, CEO**

978-878-9505

[steveshum@invobioscience.com](mailto:steveshum@invobioscience.com)

#### **Investors**

##### **Lytham Partners, LLC**

##### **Robert Blum**

602-889-9700

[INVO@lythampartners.com](mailto:INVO@lythampartners.com)

 View original content to download

multimedia:<https://www.prnewswire.com/news-releases/invo-bioscience-to-report-first-quarter-2022-financial-results-on-monday-may-16-2022-301542951.html>

SOURCE INVO Bioscience, Inc.